Cancer Trials: Patient-Reported, Overall Side Effect Impacts Should Be Measured, US FDA Says
Executive Summary
A single-item instrument can capture cumulative effects of low-grade drug toxicities, informing dose selection and de-risking development programs. However, administration of those measures at baseline in treatment-naïve patients is problematic, and practical challenges and regulatory uncertainties have inhibited broad adoption by sponsors, FDA workshop participants say.